



ASX Announcement

7 May 2020

**Atomo receives additional order for COVID-19 test devices**  
***Takes total COVID-19 test orders to 1.369 million***

**SYDNEY Australia, Thursday, 7 May 2020:** Australian rapid blood test company Atomo Diagnostics Limited ACN 142 925 684 (**Atomo**) is pleased to announce that it has received an additional unscheduled purchase order from French diagnostics company, NG Biotech, SAS (**NG Biotech**) to supply a further 422,000 integrated blood test devices for the rapid blood based testing of antibodies produced in response to COVID19.

The additional order for the period through to 31 July 2020, follows earlier purchase orders totaling 947,200 devices, received between late March and mid-April. It takes the total number of devices ordered by NG Biotech over the last six weeks to 1.369 million.

Atomo Co-Founder and Managing Director John Kelly said, “We are excited about continuing to scale up our supply to NG Biotech as it starts to rollout the COVID-19 rapid test in France. We remain in active discussions with NG Biotech regarding the potential expansion of our COVID-19 partnership across other territories and intended uses.”

The NG Biotech rapid test is CE Marked for professional use for COVID-19 testing in Europe. Results are obtained from a drop of blood in 15 minutes and indicate if the person has antibodies in their blood as a result of having been infected with the virus.

“Discussions with two US-based companies in relation to commercialisation of COVID-19 tests (subject to FDA approval) are progressing positively and we continue to have discussions related to the supply of COVID-19 tests to the Australian market,” Mr Kelly said.

Atomo's planned expansion of its production capacity in order to meet the anticipated ongoing demand for its rapid test devices is making substantial progress, with the first phase of additional capacity scheduled to come online in July this year and further capacity increases due during the second half of 2020.

For more information, please contact:

Jane Lowe

IR Department

[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

Phone: +61 411 117 774

John Kelly

Managing Director, Atomo Diagnostics Limited

[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)

Phone: +61 401 922 279

*This announcement was authorised by John Kelly, Managing Director.*

## **About Atomo**

Atomo Diagnostics Limited is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including HIV, COVID-19, and viral vs bacterial differentiation.

See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com).